ocriplasmin - search results

United States - English - NLM (National Library of Medicine)

jetrea- ocriplasmin injection, solution

thrombogenics inc. - ocriplasmin (unii: 7v6he3dm5a) (ocriplasmin - unii:7v6he3dm5a) - ocriplasmin 1.25 mg in 1 ml - jetrea ® is a proteolytic enzyme indicated for the treatment of symptomatic vitreomacular adhesion. none teratogenic effects pregnancy category c. animal reproduction studies have not been conducted with ocriplasmin. there are no adequate and well-controlled studies of ocriplasmin in pregnant women. it is not known whether ocriplasmin can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. the systemic exposure to ocriplasmin is expected to be low after intravitreal injection of a single 0.125 mg dose. assuming 100% systemic absorption (and a plasma volume of 2700 ml), the estimated plasma concentration is 46 ng/ml. jetrea should be given to a pregnant woman only if clearly needed. it is not known whether ocriplasmin is excreted in human milk. because many drugs are excreted in human milk, and because the potential for absorption and harm to infant growth and development exists, caution should be exercised when jetrea is administered to a nursing woman. the

Australia - English - Department of Health (Therapeutic Goods Administration)

jetrea ocriplasmin 0.5 mg/0.2 ml concentrated solution for intravitreal injection

i-care pharma distributors pty ltd - ocriplasmin -

Australia - English - Department of Health (Therapeutic Goods Administration)

jetrea rtu ocriplasmin (ryp) 0.375 mg/0.3 ml solution for intravitreal injection vial

i-care pharma distributors pty ltd - ocriplasmin, quantity: 1.25 mg/ml - injection, solution - excipient ingredients: mannitol; citric acid monohydrate; sodium chloride; sodium hydroxide; hydrochloric acid; water for injections - jetrea rtu is indicated in adults for the treatment of vitreomacular traction (vmt), including when associated with macular hole of diameter less than or equal to 400 microns.

New Zealand - English - Medsafe (Medicines Safety Authority)

jetrea

pharmaco (nz) ltd - ocriplasmin 2.5 mg/ml - concentrate for injection - 2.5 mg/ml - active: ocriplasmin 2.5 mg/ml excipient: citric acid monohydrate mannitol sodium hydroxide water for injection - jetrea is indicated in adults for the treatment of vitreomacular traction (vmt), including when associated with macular hole of diameter less than or equal to 400 microns.

European Union - English - EMA (European Medicines Agency)

jetrea

inceptua ab - ocriplasmin - retinal diseases - ophthalmologicals - jetrea is indicated in adults for the treatment of vitreomacular traction (vmt), including when associated with macular hole of diameter less than or equal to 400 microns.